161 related articles for article (PubMed ID: 37229458)
21. Effect of breast cancer as the first or second primary cancer on the prognosis of women with thyroid cancer: a SEER database analysis.
Huang J; Huang Y; Zhou L; Chen S; Chen D; Wei W; Zhang C; Wang M; Zhou W; Zeng W; Liu Z; Guo L
Transl Cancer Res; 2020 Nov; 9(11):6955-6962. PubMed ID: 35117303
[TBL] [Abstract][Full Text] [Related]
22. Overexpressed VDAC1 in breast cancer as a novel prognostic biomarker and correlates with immune infiltrates.
Fang Y; Liu J; Zhang Q; She C; Zheng R; Zhang R; Chen Z; Chen C; Wu J
World J Surg Oncol; 2022 Jun; 20(1):211. PubMed ID: 35729567
[TBL] [Abstract][Full Text] [Related]
23. Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics.
Li CY; Xiong DD; Huang CQ; He RQ; Liang HW; Pan DH; Wang HL; Wang YW; Zhu HW; Chen G
Med Sci Monit; 2017 Apr; 23():1857-1871. PubMed ID: 28416776
[TBL] [Abstract][Full Text] [Related]
24. Identification of the EMT-Related Genes Signature for Predicting Occurrence and Progression in Thyroid Cancer.
Li Q; Jiang S; Feng T; Zhu T; Qian B
Onco Targets Ther; 2021; 14():3119-3131. PubMed ID: 34012269
[TBL] [Abstract][Full Text] [Related]
25. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
26. Key molecules associated with thyroid carcinoma prognosis: A study based on transcriptome sequencing and GEO datasets.
Bai M; Ke S; Yu H; Xu Y; Yu Y; Lu S; Wang C; Huang J; Ma Y; Dai W; Wu Y
Front Immunol; 2022; 13():964891. PubMed ID: 36059514
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer.
Li XJ; Wen R; Wen DY; Lin P; Pan DH; Zhang LJ; He Y; Shi L; Qin YY; Lai YH; Lai JN; Yang JL; Lai QQ; Wang J; Ma J; Yang H; Pang YY
Mol Med Rep; 2020 Sep; 22(3):2199-2218. PubMed ID: 32705210
[TBL] [Abstract][Full Text] [Related]
28. Risk of second primary breast cancer among cancer survivors: Implications for prevention and screening practice.
Cheng Y; Huang Z; Liao Q; Yu X; Jiang H; He Y; Yao S; Nie S; Liu L
PLoS One; 2020; 15(6):e0232800. PubMed ID: 32497148
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide scanning for CHD1L gene in papillary thyroid carcinoma complicated with type 2 diabetes mellitus.
Kang YY; Li JJ; Sun JX; Wei JX; Ding C; Shi CL; Wu G; Li K; Ma YF; Sun Y; Qiao H
Clin Transl Oncol; 2021 Dec; 23(12):2536-2547. PubMed ID: 34245428
[TBL] [Abstract][Full Text] [Related]
30. The G Protein-Coupled Estrogen Receptor (GPER) Expression Correlates with Pro-Metastatic Pathways in ER-Negative Breast Cancer: A Bioinformatics Analysis.
Talia M; De Francesco EM; Rigiracciolo DC; Muoio MG; Muglia L; Belfiore A; Maggiolini M; Sims AH; Lappano R
Cells; 2020 Mar; 9(3):. PubMed ID: 32143514
[TBL] [Abstract][Full Text] [Related]
31. Rac3 Expression and its Clinicopathological Significance in Patients With Bladder Cancer.
Chen M; Nie Z; Cao H; Gao Y; Wen X; Zhang C; Zhang S
Pathol Oncol Res; 2021; 27():598460. PubMed ID: 34257551
[No Abstract] [Full Text] [Related]
32. Possible association between breast thyroid carcinoma: analysis of risk factors.
Del Rio P; Viani L; Bonati E; Marina M; Arcuri MF; Ceresini G
Ann Ital Chir; 2020; 91():173-180. PubMed ID: 32719185
[TBL] [Abstract][Full Text] [Related]
33. Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer.
Xu W; Wang Y; Wang Y; Lv S; Xu X; Dong X
Int J Mol Med; 2019 Aug; 44(2):390-404. PubMed ID: 31198978
[TBL] [Abstract][Full Text] [Related]
34. Identifying liver metastasis-related hub genes in breast cancer and characterizing
Chen M; Zheng W; Fang L
PeerJ; 2023; 11():e15311. PubMed ID: 37180578
[TBL] [Abstract][Full Text] [Related]
35. Survival of Patients with First and Metachronous Second Primary Breast Cancer or Lung Cancer Malignancy: Comparisons Using the SEER Database.
Zhong M; He X; Lei K
Adv Ther; 2020 May; 37(5):2236-2245. PubMed ID: 32274747
[TBL] [Abstract][Full Text] [Related]
36. Relationship between metastasis and second primary cancers in women with breast cancer.
Li C; Liu M; Li J; Zhao X; Wang Y; Chen X; Wang W; Sun S; Feng C; Cai Y; Wu F; Du C; Zhang Y; Zhang S; Qu J
Front Oncol; 2022; 12():942320. PubMed ID: 36248962
[TBL] [Abstract][Full Text] [Related]
37. Identification of a novel glycolysis-related signature to predict the prognosis of patients with breast cancer.
He M; Hu C; Deng J; Ji H; Tian W
World J Surg Oncol; 2021 Oct; 19(1):294. PubMed ID: 34600547
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value and association with epithelial-mesenchymal transition and molecular subtypes of the proteoglycan biglycan in advanced bladder cancer.
Schulz GB; Grimm T; Sers C; Riemer P; Elmasry M; Kirchner T; Stief CG; Karl A; Horst D
Urol Oncol; 2019 Aug; 37(8):530.e9-530.e18. PubMed ID: 31176613
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer.
Cui H; Ren X; Dai L; Chang L; Liu D; Zhai Z; Kang H; Ma X
Front Immunol; 2023; 14():1145552. PubMed ID: 36969219
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
